Studies · Authored work

Studies

Authored studies with source titles, DOIs where issued, Wikidata items, and official deposits. Last Part Standing is a book, not a study, and is not listed here.

Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. The work referenced here describes published scientific literature. It does not describe an available treatment.

Studies

• Mesenchymal Stromal Cell-Derived Exosomes and Extracellular Vesicles Across Therapeutic Indications A Structured Review of Published Preclinical and Early-Phase Clinical Study Designs, Administration Parameters, and Reported Outcomes

  2026 · Andrew Jonathan Hillman

  DOI: 10.5281/zenodo.21209815 (paper page) · Zenodo record · Wikidata Q140443625 · Official file (MSC_Exosome_EV_Literature_Review.docx) · Download PDF

• Mesenchymal Stem Cell-Derived Extracellular Vesicles for Tissue Repair Across Multiple Body Systems: A Narrative Review

  2026 · Andrew Jonathan Hillman

  DOI: 10.5281/zenodo.21047848 (paper page) · Zenodo record · Wikidata Q141085999 · Official file (Mesenchymal_Stem_Cell_Derived_Extracellu.docx) · Download PDF

• Wharton's Jelly Mesenchymal Stem Cell-Derived Exosomes as an Adjunctive and Alternative Therapeutic Strategy in Spinal Disc Repair, Post-Surgical Recovery, and as a Replacement for FDA-Unindicated Epidural Corticosteroid Injections

  2026 · Hillman, A. J., et al.

  DOI: 10.5281/zenodo.20978822 (paper page) · Zenodo record · Wikidata Q140370794 · Official file (WJ_MSC_Exosomes_Spine_Paper.docx) · Download PDF

• Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes

  2026 · Andrew Jonathan Hillman

  Academia.edu · Wikidata Q140368055 · Author profile (publications)

• Mesenchymal Stem Cell-Derived Exosomes from Wharton's Jelly: The Gold Standard for Safe, Compliant Regenerative Medicine

  2026 · Andrew Jonathan Hillman

  DOI: 10.5281/zenodo.20974697 (paper page) · Version DOI: 10.5281/zenodo.20974698 · Zenodo record · Wikidata Q141086000

• From our Research, The Biologics Paradigm: Wharton's Jelly Mesenchymal Exosomes as a Section 351(a) Drug vs. The Section 361 Regulatory Grey Market

  2026 · Andrew Jonathan Hillman · Investigational literature. Not FDA-approved. Contrasts the Section 351(a) biologic pathway with the Section 361 regulatory grey market.

  DOI: 10.5281/zenodo.21142612 (paper page) · Version DOI: 10.5281/zenodo.21142613 · Zenodo record · OpenAlex W7167067735

• Wharton's Jelly Mesenchymal Stem Cell-Derived Exosomes: Dosing Protocols, Manufacturing Quality Systems, Drug Master File Requirements, cGMP Compliance, and the Complete Federal and State Regulatory Framework Under the FDA 351(a) CBER Pathway

  2026 · Andrew Jonathan Hillman · Regulatory monograph. Zenodo DOI pending. Distinct from the Biologics Paradigm paper above.

  Academia.edu publications profile · ORCID · Zenodo DOI pending

• Mesenchymal Exosome Research: Top Studies by Body System

  Andrew Jonathan Hillman

  ResearchGate 408344668

• WJ MSC Exosome Clinical Study v3

  Andrew Jonathan Hillman

  ResearchGate 408344955

• Targeted Osmotic Lysis (TOL 2.0): Digoxin-Mediated Na/K-ATPase Inhibition Combined with Pulsed Electromagnetic Frequency

  2026 · Andrew Jonathan Hillman · Investigational. Not approved by the FDA for any indication. Not available as a treatment.

  Academia.edu · Wikidata Q140368059

Related papers: structured review of MSC exosome studies; narrative review of MSC extracellular vesicles in tissue repair; Wharton's jelly exosomes in spinal disc repair research; Wharton's jelly MSC exosomes under Section 351(a); 351(a) classification paper on Wharton's jelly exosomes